Multivariate analysis revealed CXCR4 expression and unfavorable cytogenetics as independent prognostic factors. We conclude that CXCR4 expression in AML is an independent prognostic predictor for disease relapse and survival that can rapidly and easily be determined at disease presentation. These findings warrant further investigation into the role of CXCR4 in AML, and suggest that CXCR4 should be incorporated into the risk assessment of AML patients.
Introduction
Despite major improvements in the understanding and treatment of certain leukemias during the past years, the overall survival of patients with acute myelogenous leukemia (AML) remains poor and new prognostic markers and therapeutic strategies are urgently needed. Several prognostic markers have been described in AML, including age, performance status, karyotype, white blood cell count (WBC), serum lactate dehydrogenase (LDH), presence or absence of an antecedent hematologic disorder (e.g. myelodysplasia), and the presence of distinct cytogenetic abnormalities [1] [2] [3] . Cytogenetic abnormalities can be detected in approximately 60% of AML patients and represent the most important predictor for responses to therapy and relapse probability. Depending upon cytogenetic characteristics, patients can be classified into low risk, intermediate risk, or high-risk groups 4, 5 . However, there is substantial heterogeneity within these groups. 35-50% of AML patients display a normal karyotype, which can further be subdivided using predictive molecular markers, such as mutations in the fetal liver tyrosine kinase-3 (FLT3) gene and the mixed-lineage leukemia (MLL) gene 6, 7 .
Several studies indicated that adhesion to marrow stromal cells affects the survival and proliferation of AML cells 8, 9 and protects AML cells from chemotherapy in vitro 10 and in vivo 11 . Adhesion molecules, in particularly the very late antigen-4 (VLA-4) and VLA-5 integrins, are considered essential for AML cell adhesion to respective stromal ligands (fibronectin) 12 and for protection of AML cells from spontaneous or drug-induced apoptosis 11, 13 .
However, adhesion molecules (selectins, integrins) alone are responsible only for initial, transient adhesion events; a second step triggered by chemokine receptor activation is necessary to transform reversible into firm adhesion and directional migration 14, 15 .
Stromal cell-derived factor-1 (SDF-1), which now is designated as CXCL12 16 , is a homeostatic chemokine that is constitutively secreted by marrow stromal cells. CXCL12 signals through CXCR4, which in turn plays an important role in hematopoiesis, development, and organization of the immune system. CXCL12
and CXCR4 gene-deleted mice displayed an identical, lethal phenotype, [17] [18] [19] [20] . 
Materials and Methods

Patients, flow cytometry
Statistical analysis:
Statistical analysis was performed using the SAS 8. The overall survival was calculated from the date of first diagnosis to date of death. The relapse-free survival was calculated from the date of first diagnosis to date of relapse included antecedent complete remission (CR). The significance of difference between survival curves was calculated by log-rank test. Groupwise comparisons of the distributions of variables were performed with the generalized Wilcoxon test. Cox regression and was used to identify differences in survival due to prognostic factors. P values < 0.05 were considered significant. As possible prognostic factors, we included age, sex, white-blood cell count (WBC), cytogenetics, serum lactat dehydrogenase (LDH), platelets, and CXCR4 expression levels as MFIR. 
Association between CXCR4 expression and clinical data
The characteristics of all AML patients are displayed in Table 1 . Compared to the AML patient population evaluated by Rombouts et al. 33 , our patient population was older, and had a higher proportion of patients with unfavorable cytogenetics. In Table 2 , we display the patients' characteristics for each of the three different CXCR4 expression groups (low, intermediate, high). We noticed higher white blood cell counts, LDH, a higher frequency of blast persistence, relapses, and deaths in patients with higher CXCR4 expression (groups B, C), and a shorter overall and relapse-free survival, when compared to patients with low CXCR4 expression (group A).
High and intermediate CXCR4 expression on AML cells is associated with a decreased overall survival and relapse-free survival
To determine the prognostic impact of CXCR4 expression on AML cells, we In order to define the prognostic significance of the observed correlation between disease outcome and CXCR4 expression as well as the prognostic relevance of other parameter including sex, age, WBC, LDH, and cytogenetic abnormalities, multivariate and univariate Cox regression analysis was performed, and the results are displayed in Table 4 . In univariate analysis, unfavorable cytogenetics, and CXCR-4 MFIRs groups A through C were significant predictive factors resulting in a reduced OS and RFS, whereas LDH was a significant predictive factor only for OS and WBC only for RFS (Tab. 4).
Cox proportional hazards analysis of CXCR4 expression (as numerical MFIR
values) and other prognostic markers as predictors of the time from diagnosis to relapse or death revealed that the hazard ratio associated with CXCR4 was 2.699 (95 percent confidence interval, 1.327 to 5.489) for overall survival and 3.853 (95 percent confidence interval, 1.298 to 11.442) for relapse-free survival in univariate analysis. In multivariate Cox regression analysis, only unfavorable cytogenetics and CXCR4 expression by AML cells were significant predictive factors for overall survival. Considering CXCR4 expression as risk factor for relapse (P=0.01), the presence of other risk factors including cytogenetics lost their impact for risk of relapse (Tab. 4).
Discussion
In this study we found a strong association between the surface expression of CXCR4 in CD34-and/or CD117-positve AML cells and overall and relapse-free survival. Patients that had a low CXCR4 expression (MFIR <5) had a significantly longer relapse-free and overall survival than patients that displayed intermediate or high CXCR4 levels. Multivariate analysis revealed that CXCR4 is a prognostic marker that is independent of other previously established prognostic markers, such as cytogenetic abnormalities, LDH, leukocytosis, or age. These findings confirm the study by Rombouts and colleagues, which demonstrated a correlation between CXCR4 expression on AML cells, Flt3 mutational status, and poor outcome 33 . However, in contrast to this study, which used frozen AML cell samples that previously had been enriched for AML cells
by Ficoll separation and T-cell depletion, we used fresh marrow aspirates and a whole blood lysis method during preparation for flow cytometry. The conditions used in our study are commonly used during routine immunophenotyping of leukemias, demonstrating that CXCR4 staining of AML cells can be incorporated into routine flow cytometry analysis, using PE-conjugated 12G5
anti-CXCR4 antibodies. 12G5 is the initially described and most widely utilized antibody clone to detect CXCR4 34 . The data analysis approach is also different between both studies: Rombouts et al. defined 1% or 20% of CXCR4-positive AML cells co-expressing CD34 as cut-points to define poor prognostic subgroups, whereas this study utilizes mean fluorescence intensity ratios Kaplan-Meier analysis (Fig. 2 A, C) and therefore it is questionable whether there is a need for distinguishing between intermediate and high CXCR4. As displayed in Table 2 , groups A through C had a clear trend for higher WBCs, shorter overall and relapse-free survival, and we therefore recommend the use of these three groups for a subsequent, larger study to determine if intermediate Moreover, the mean fluorescence intensity ratio (MFIR) for CXCR4 is displayed. Figure 2 . Impact of CXCR4 expression on overall survival (OS) and relapse-free survival (RFS) in AML patients. These graphs display Kaplan-Meier estimates of OS (Fig. 2 A, B) and RFS ( Fig. 2 C, D Table 4 For personal use only. by on April 17, 2008 . www.bloodjournal.org From
